OMDA
HealthcareOmada Health · Medical - Healthcare Information Services · $980M
What is Omada Health?
Omada Health is a San Francisco-based virtual-care company focused on managing chronic conditions through digital programs delivered between doctor visits. Its clinically validated approach targets cardiometabolic disease, musculoskeletal care, and behavioral health.
Omada Health generates revenue by partnering with employers, health plans, and government payers to deliver digital therapeutic programs at scale. Rather than replacing in-person care, the platform extends clinical support into patients' daily lives — using coaching, connected devices, and behavioral science. Programs are designed around chronic conditions that drive outsized healthcare costs, positioning Omada as a cost-reduction tool for payers while improving outcomes for members.
Omada Health is headquartered in San Francisco, California.
- Digital cardiometabolic disease management programs
- Virtual musculoskeletal care and physical therapy support
- Behavioral health coaching delivered between clinical visits
- Employer and health-plan partnership model for program distribution
Is OMDA a Good Stock to Buy?
UQS Score rates OMDA as Below Average overall.
The standout pillar for Omada Health is Growth, rated Strong — reflecting the company's rapid expansion in a large and underpenetrated virtual-care market. Risk is rated Neutral, suggesting the near-term operational profile is not unusually volatile relative to sector peers.
Both the Quality and Moat pillars are rated Weak, pointing to limited competitive differentiation and underlying business fundamentals that trail stronger peers. Valuation is rated Elevated, meaning the market may already be pricing in an optimistic growth scenario.
Pro members can see the exact pillar breakdown and full financial metrics behind the OMDA score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does OMDA pay dividends?
No — Omada Health does not currently pay a dividend.
Omada Health does not currently pay a dividend. As a growth-stage digital health company, capital is directed toward expanding its program offerings, deepening payer relationships, and scaling its member base rather than returning cash to shareholders. Income-focused investors should factor this into their assessment.
When does OMDA report earnings?
Omada Health reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
The company's Growth pillar is rated Strong, suggesting revenue trajectory has been a relative bright spot. However, Quality remains Weak, indicating that profitability and cash generation have not yet matched top-line expansion. For the most current results, check Omada's investor relations page directly.
For the most recent quarter's results, see Omada Health's investor relations page.
OMDA Price History
-21.9% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
OMDA Long-term Outlook
Omada Health's fundamental outlook is shaped by a strong Growth profile set against weak Quality and Moat ratings. The digital chronic-care market continues to expand as payers seek scalable cost-reduction tools, which supports the top-line trajectory. However, the path to durable profitability remains a key question, and an Elevated Valuation rating suggests limited margin for error if growth slows or competitive pressure intensifies.
Growth drivers
- Expanding employer and health-plan partnerships in a large chronic-care market
- Growing demand for cost-effective digital alternatives to in-person chronic disease management
- Potential to add new condition categories and deepen existing program offerings
Key risks
- Weak Moat rating signals limited barriers to entry from well-resourced digital health competitors
- Elevated Valuation leaves little room for execution shortfalls or slower-than-expected enrollment growth
- Weak Quality pillar reflects ongoing pressure on profitability and cash flow generation
OMDA vs Peers
Omada Health operates in a broader digital health and healthcare technology landscape alongside companies with distinct business models.
GoodRx focuses on prescription price transparency and pharmacy savings rather than chronic condition management programs.
Schrödinger applies computational drug discovery technology, operating in a fundamentally different part of the healthcare value chain.
Certara provides biosimulation software and regulatory science services to drug developers, distinct from direct patient-facing virtual care.
Frequently Asked Questions
What does Omada Health do?
Omada Health delivers digital therapeutic programs for chronic conditions including cardiometabolic disease, musculoskeletal care, and behavioral health. The platform extends clinical support between doctor visits through coaching, connected devices, and behavioral science. It partners with employers and health plans to distribute programs at scale.
Does OMDA pay dividends?
No, Omada Health does not currently pay a dividend. As a growth-stage company, available capital is reinvested into expanding its programs and payer partnerships. Investors seeking regular income should note this when evaluating the stock.
When does OMDA report earnings?
Omada Health follows a standard quarterly earnings cadence for US-listed companies. For the exact schedule and most recent results, visit Omada Health's official investor relations page, as specific dates are subject to change.
Is OMDA a good stock to buy?
UQS Score rates OMDA as Below Average overall. Growth is rated Strong, but Quality and Moat are both Weak, and Valuation is Elevated. That combination means the stock carries meaningful execution risk. The complete pillar breakdown is available to Pro members on UQS Score.
Is OMDA overvalued?
The UQS Valuation pillar for OMDA is rated Elevated, suggesting the current market price may already reflect an optimistic growth outlook. When Quality and Moat are simultaneously weak, an elevated valuation leaves limited buffer against operational disappointments.
How does OMDA compare to its competitors?
Omada Health competes in the broader digital health space alongside companies like GoodRx, Schrödinger, and Certara — each with distinct models. Omada's differentiation lies in its clinically validated chronic-condition programs delivered through payer partnerships, though its Moat is rated Weak relative to the sector.
What is OMDA's market cap bracket?
Omada Health is classified as a small-cap company. This places it in a segment of the market that can offer higher growth potential but also carries greater volatility and liquidity risk compared to large- or mega-cap peers.
Who founded Omada Health?
Omada Health was co-founded by Sean Duffy and Adrian James. Founding context and leadership history are widely available through the company's official website and public filings.
Is OMDA a long-term quality indicator?
From a quality-indicator perspective, OMDA's long-term profile is mixed. Growth is rated Strong, which supports a long-term expansion narrative. However, Weak Quality and Moat ratings suggest the business has not yet built the durable competitive advantages typically associated with high-quality long-term holdings. Pro members can view the full analysis.
What is the main competitive advantage of Omada Health?
Omada's primary differentiation is its clinically validated program design and established payer relationships, which create some switching friction. However, the UQS Moat pillar is rated Weak, indicating these advantages are not yet considered durable or wide enough to strongly protect against competition.
What sector does OMDA belong to?
Omada Health operates in the Healthcare sector, specifically within the digital health and virtual care segment. It targets the chronic disease management market, working alongside traditional healthcare providers rather than replacing them.
Is OMDA a growth stock or value stock?
Based on its UQS pillar profile, OMDA leans firmly toward the growth category — the Growth pillar is rated Strong. However, the Valuation pillar is Elevated, meaning investors are already paying a premium for that growth potential, which is a consideration for value-oriented investors.
Unlock Full OMDA Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓See the exact UQS Score and all five pillar ratings
- ✓View full financial metrics behind the Quality and Moat scores
- ✓Access the complete Growth and Valuation breakdown
- ✓Compare OMDA side-by-side with sector peers
- ✓Get the complete analyst view available to Pro members
Pro Analysis
OMDA — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 46.0 | 21.2 | 29.0 | 100.0 | 47.1 | 42.8 | 0.0 |
| May 20, 2026 | 46.0 | 21.2 | 29.0 | 100.0 | 47.1 | 42.5 | 0.0 |
| May 18, 2026 | 46.0 | 21.2 | 29.0 | 100.0 | 47.1 | 42.8 | -0.3 |
| May 14, 2026 | 46.3 | 21.4 | 29.0 | 100.0 | 47.1 | 44.1 | -0.5 |
| May 12, 2026 | 46.8 | 21.8 | 29.0 | 100.0 | 47.1 | 47.1 | +6.5 |
| May 10, 2026 | 40.3 | 0.0 | 29.0 | 100.0 | 36.9 | 50.1 | -3.5 |
| May 7, 2026 | 43.8 | 21.6 | 29.0 | 100.0 | 47.1 | 27.0 | -0.4 |
| May 3, 2026 | 44.2 | 21.6 | 29.0 | 100.0 | 47.1 | 30.0 | -0.9 |
| Apr 26, 2026 | 45.1 | 21.6 | 29.0 | 100.0 | 47.1 | 36.0 | -0.2 |
| Apr 19, 2026 | 45.3 | 21.6 | 29.0 | 100.0 | 47.1 | 37.0 | -1.8 |
OMDA — Pillar Breakdown
Quality
— 21.2/100 (25%)Omada Health currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 100.0/100 (20%)Omada Health is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 47.1/100 (15%)Omada Health has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 42.8/100 (15%)Omada Health has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Moat
— 29/100 (25%)Omada Health operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for OMDA.
Score Composition
Financial Data
More Stock Analysis
How is the OMDA UQS Score Calculated?
The UQS (Unified Quality Score) for Omada Health is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Omada Health's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Omada Health is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.